News
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387 -
COMMUNIQUÉ RÉGLEMENTÉ
Statement of transactions in own shares from September 23, 2024 to September 27, 2024
-
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration des transactions sur actions propres réalisées du 23/09/2024 au 27/09/2024
-
COMMUNIQUÉ DE PRESSE
Medacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy
Medacta Group SA hosts its first Capital Markets Day, presenting responsible innovation and effective growth strategy to investors. Key areas include patient-focused commitment, product development, and global market expansion -
-
COMMUNIQUÉ DE PRESSE
beaconsmind Group announces 1H2024 with strong profitable growth reaffirming previously provided guidance for full year 2024
beaconsmind Group reports strong profitable growth in 1H2024 with revenue up by 122% and EBITDA up by 740% compared to previous periods. Cash breakeven achieved and positive free cash flow expected. Major client wins and expansion plans highlighted -
COMMUNIQUÉ DE PRESSE
Energiekontor AG: Four solar and wind projects launched – Energiekontor starts construction on 125 megawatts and expands its portfolio to more than 610 megawatts in the future
Energiekontor AG launches four solar and wind projects, expanding its portfolio to over 610MW. Projects to strengthen electricity generation segment, with loan approvals driving project pipeline realization -
COMMUNIQUÉ DE PRESSE
EnviTec Biogas reports strong business performance for H1 2024 and confirms its forecast
EnviTec Biogas reports strong business performance for H1 2024 and confirms its forecast with total output at EUR 181.6 million and revenues at EUR 179.4 million. EBITDA and EBT slightly reduced compared to H1 2023